Discovery of a highly potent glucocorticoid for asthma treatment

about

Erratum: Discovery of a highly potent glucocorticoid for asthma treatment.

P921

Q42808631-9166416A-81A6-4304-B5F2-260E453CDE76

P921

Discovery of a highly potent glucocorticoid for asthma treatment

Item

http://www.wikidata.org/entity/Q36769629

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Discovery of a highly potent glucocorticoid for asthma treatment

@ast

Discovery of a highly potent glucocorticoid for asthma treatment

@en

type

Item

label

Discovery of a highly potent glucocorticoid for asthma treatment

@ast

Discovery of a highly potent glucocorticoid for asthma treatment

@en

prefLabel

Discovery of a highly potent glucocorticoid for asthma treatment

@ast

Discovery of a highly potent glucocorticoid for asthma treatment

@en

P1476

Discovery of a highly potent glucocorticoid for asthma treatment

@en

P2093

H Eric Xu

http://www.w3.org/2001/XMLSchema#string

Jianshuang Li

http://www.w3.org/2001/XMLSchema#string

Jingjing Shi

http://www.w3.org/2001/XMLSchema#string

Kevin Weaver

http://www.w3.org/2001/XMLSchema#string

Nanyan Wu

http://www.w3.org/2001/XMLSchema#string

Qian Xie

http://www.w3.org/2001/XMLSchema#string

Sok Kean Khoo

http://www.w3.org/2001/XMLSchema#string

Tao Yang

http://www.w3.org/2001/XMLSchema#string

Wei Yi

http://www.w3.org/2001/XMLSchema#string

Xiang Gao

http://www.w3.org/2001/XMLSchema#string

P2507

Erratum: Discovery of a highly potent glucocorticoid for asthma treatment.

P2860

Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects

The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression

Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy

Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition

X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain

Structures and mechanism for the design of highly potent glucocorticoids

Mometasone furoate is a less specific glucocorticoid than fluticasone propionate

Glucose kinetics in the collagen-induced arthritis model: an all-in-one model to assess both efficacy and metabolic side effects of glucocorticoids

limma powers differential expression analyses for RNA-sequencing and microarray studies

Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response.

P2888

celldisc.2015.35

P31

scholarly article

P356

10.1038/CELLDISC.2015.35

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Karsten Melcher

P577

2015-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

287127672

http://www.w3.org/2001/XMLSchema#string

P698

27066265

http://www.w3.org/2001/XMLSchema#string

P932

4822341

http://www.w3.org/2001/XMLSchema#string

Discovery of a highly potent glucocorticoid for asthma treatment

about

P921

P921

Discovery of a highly potent glucocorticoid for asthma treatment

description

name

type

label

prefLabel

P1433

P1476

P2093

P2507

P2860

P2888

P31

P356

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2507

P2860

P2888

P31

P356

P478

P50

P577

P5875

P698

P932